How long will I receive my bispecific antibody therapy?

As of July 2025, bispecific antibody therapy has been designed to be given until myeloma progression or until the side effects outweigh the benefits of treatment. 

Keep an open communication with your healthcare team about how you are feeling about the treatment. While some patients have hardly any side effects, everyone is different, and you might have a harder time with the drug’s side effect profile than someone else.